Biosynthetic gene cluster of cystobactamids and use thereof
By utilizing the SDUN13-cys gene cluster, a biosynthetic gene for cystobactamids, myxobacteria enhance their predation ability against pathogenic microorganisms, thus solving the ecological crisis and drug resistance problems caused by chemically synthesized fungicides and achieving effective predation in agricultural biological control.
Patent Information
- Application Number
- CN202610361323.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2026-03-24
- Publication Date
- 2026-07-07
- Estimated Expiration
- 2046-03-24
AI Technical Summary
There is currently no research on cystobactamids compounds for enhancing the predatory activity of myxobacteria against plant pathogenic fungi. The ecological crisis and pathogen resistance caused by chemically synthesized fungicides are prominent issues.
A biosynthetic gene cluster for cystobactamids-like compounds, named SDUN13-cys, derived from the destructive Corallococcus interemptorSDUN13, is provided. It contains 21 open reading frames and is used to promote the predation of pathogenic microorganisms by myxobacteria. The predation ability is enhanced by constructing and expressing cystobactamids-like compounds.
It significantly improves the predation efficiency of myxobacteria against pathogenic microorganisms, reduces environmental stress and the development of drug resistance, broadens the application scenarios of cystobactamids, and has good potential for agricultural biological control.
Smart Images

Figure CN121896251B_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the fields of agricultural biotechnology and microbial engineering technology, specifically relating to a biosynthetic gene cluster of cystobactamids and its application. Background Technology
[0002] Plant fungal diseases not only cause direct yield losses but also lead to a significant decline in the quality of agricultural products, resulting in severe economic losses. For more than half a century, chemically synthesized fungicides have been the core means of controlling plant fungal diseases. However, excessive and improper use has led to a serious ecological crisis and the problem of pathogen resistance, plunging disease control into a major predicament.
[0003] Myxobacteria possess the ability to actively prey on and lyse other bacteria and fungi, a process that relies on a sophisticated arsenal of molecular weapons comprised of various secreted secondary metabolites. Studies show that myxobacteria originating from the Sporocystaceae family... Cystobacter Cystobactamids from sp. CbG35 exhibit broad-spectrum and potent antibacterial activity against a variety of Gram-negative and Gram-positive bacteria, particularly effective in inhibiting clinical isolates, including multidrug-resistant strains. In addition to direct antibacterial effects, studies have found that cystobactamids may inhibit the cholesterol receptor SCARB1, blocking the cellular invasion of pathogens such as hepatitis C virus, suggesting potential antiviral applications. Furthermore, cystobactamids themselves, or the myxobacteria that produce them, can be used in agricultural biological control, such as controlling Verticillium wilt in cotton. Therefore, these compounds also possess significant application potential in the field of agricultural biological control.
[0004] However, there are currently no research reports on whether cystobactamids-like compounds can enhance the predatory activity of myxobacteria against plant pathogenic fungi. Summary of the Invention
[0005] To address the shortcomings of the prior art, the purpose of this invention is to provide a biosynthetic gene cluster of cystobactamids and its applications.
[0006] To achieve the above objectives, the present invention adopts the following technical solution:
[0007] In a first aspect, the present invention provides a biosynthetic gene cluster of cystobactamids, the nucleotide sequence of which is shown in SEQ ID NO:1.
[0008] The biosynthetic gene cluster of cystobactamids is derived from the destroyer coral cocci. Corallococcus killer SDUN13 encodes cystobactamids-like compounds and has been named the cys gene cluster. (The text then mentions *Cytoplasma coral*, a species of cystobacter.) Corallococcus killer SDUN13 has been deposited at the China General Microbiological Culture Collection Center (CGMCC) on November 7, 2025, with accession number CGMCC No. 36542.
[0009] The cys gene cluster is 44,846 bp in length and contains 21 open reading frames (ORFs). The core biosynthetic genes are cys10 (SEQ ID NO: 2), cys11 (SEQ ID NO: 3), cys13 (SEQ ID NO: 4), and cys14 (SEQ ID NO: 5), which encode nonribosomal peptide synthase (NRPS).
[0010] In a second aspect, the present invention provides engineered bacteria containing the aforementioned biosynthetic gene clusters.
[0011] A third aspect of the present invention provides a microbial inoculant comprising the aforementioned engineered bacteria and their metabolites.
[0012] Furthermore, the preparation method of the microbial inoculant includes: inoculating the above-mentioned engineered bacteria into CTT liquid medium, culturing at 30°C with shaking for 24 h, then transferring to VY / 2 liquid medium for 48 h, collecting the bacterial cells, resuspending them in TPM buffer, and adjusting their concentration to OD. 600 ≈0.3, that is, we get the result.
[0013] A fourth aspect of the present invention provides the use of the above-described biosynthetic gene clusters or engineered bacteria in the preparation of cystobactamids-like compounds.
[0014] A fifth aspect of the present invention provides a method for preparing cystobactamids-like compounds, comprising the step of expressing a biosynthetic gene cluster of cystobactamids-like compounds in a host cell; the nucleotide sequence of the biosynthetic gene cluster of the cystobactamids-like compounds is shown in SEQ ID NO:1.
[0015] Further, the steps include: constructing the biosynthetic gene cluster of cystobactamids-like compounds onto a vector, transforming it into a host cell for culture, obtaining a culture broth, collecting the supernatant of the culture broth, and extracting and separating the supernatant to obtain cystobactamids-like compounds.
[0016] Furthermore, the culture medium was CTT+Kan liquid medium, the culture temperature was 30℃, and the culture time was 6~7 days.
[0017] Furthermore, high-performance liquid chromatography (HPLC) was used for separation, with an EF column. C18M (5μm, 250mm x 4.6mm, GALAK), UV detector, detection wavelength 280 nm, detection temperature 30℃, injection volume 10 μL, flow rate 0.8 mL / min, mobile phase A ddH2O, mobile phase B methanol, gradient elution, elution program as follows: 0-30 min: 5-100% B; 30-40 min: 100% B; 40-46 min: 5% B, collect the product after 25-30 min, i.e. cystobactamids compounds.
[0018] Furthermore, the host cell is a model strain, including *Myxococcus faecalis* DK1622.
[0019] A sixth aspect of the present invention provides the use of the cystobactamids-like compounds prepared by the above method in any of the following:
[0020] (1) Promotes the predation ability of myxobacteria on pathogenic bacteria;
[0021] (2) Inhibit plant pathogenic fungi.
[0022] Furthermore, the myxobacteria include Myxococcus , Coralloccus , Archangel , Pyxidicoccus , Nannocystis and Aggregicoccus .
[0023] Furthermore, the myxobacteria include Myxococcus stipitatus 09-20S1、 Myxococcus stocky HXWNN15 Myxococcus virescens SDUN12 Myxococcus virescens 179B01 Myxococcus virescens HXWNN29 Myxococcus virescens 122B12, Myxococcus fulvus 09-20S4 Myxococcus fulvus HXWNN20 Corallococcus macrosporus 20-3S1, Coralloccus macrosporum HXWNN19 Corallococcus killer HXWNN13 Coralloccus murderer VnMB02、 Corallococcus small HXWNN7 Corallococcus small HXWNN16 Nannocystis pusilla 09-2S35 Nannocystis pusilla QLN3, Nannocystis edens QLN2, Archangium gephyra SDU294 Archangel violet SM1-4 Pyxidicoccus deceitful 9741B01 Aggregicoccus edonensis SDU12 and Myxococcus xanthus DK1622.
[0024] Furthermore, the pathogenic bacteria include animal pathogenic bacteria and plant pathogenic fungi; the animal pathogenic bacteria include E.coli K12 A. baumannii ATCC 17978 and S.aureus ATCC12600; the plant pathogenic fungi include F. oxysporum P4 Colletotrichum musae ACCC 31244 Colletotrichum asianum P3 Fusarium oxysporum f.sp. from Cuba P4 Fusarium oxysporum f. sp. beans P5 Fusarium stinking P6 Fusarium gramineae P7 Fusarium mangosteen P8 Corynespora cashew nut P9 Nectarine sp. P11、 Fusarium wilt P12, Fusarium oxysporum ACCC 30373.
[0025] A seventh aspect of the present invention provides a method for inhibiting plant pathogenic fungi, comprising using the above-mentioned microbial inoculant to inhibit plant pathogenic fungi; wherein the plant pathogenic fungus is *Anthracnose fungus* (also known as banana anthracnose fungus). Colletotrichum musae ACCC31244).
[0026] Compared with the prior art, the technical solution of the present invention has the following beneficial effects:
[0027] This invention provides a biosynthetic gene cluster of cystobactamids-like compounds with biocontrol functions, named SDUN13-cys, with a full length of 44,846 bp and composed of 21 open reading frames (ORFs). The product of the SDUN13-cys gene cluster can effectively promote the predation of pathogenic microorganisms by various myxobacteria, including bacteria and plant pathogenic fungi. Furthermore, this invention discovers that applying cystobactamids-like compounds in mixture form to myxobacteria can significantly improve their efficiency in predating a broad spectrum of pathogenic microorganisms, opening up a completely new application area for these compounds.
[0028] This invention reveals for the first time a novel biological function of cystobactamids compounds beyond antibiotics, broadening their application scenarios: by "enhancing predators" rather than "directly killing pathogens," it reduces environmental stress and the development of drug resistance, showing great promise in the field of agricultural biological control. Attached Figure Description
[0029] Figure 1 This is a schematic diagram of the biosynthetic gene cluster structure of cystobactamids; 1 to 21 in the figure represent 21 open reading frames.
[0030] Figure 2 This is a schematic diagram illustrating the knockout of the biosynthetic gene cluster of cystobactamids-like compounds.
[0031] Figure 3 This is a schematic diagram for verifying the biosynthetic gene cluster knockout of cystobactamids-type compounds; where A represents the characteristic peak of cystobactamids-type compounds, and B represents the UV absorption spectrum corresponding to this type of characteristic peak.
[0032] Figure 4 A schematic diagram of the construction of the pBAC-Tpase-cys vector.
[0033] Figure 5 This is a liquid phase detection image of DK1622-cys.
[0034] Figure 6 This diagram illustrates how the cys gene cluster affects the predation ability of SDUN13.
[0035] Figure 7 This diagram illustrates how cystobactamids-like compounds promote the predation of pathogenic microorganisms by various myxobacteria.
[0036] Figure 8 Cystoccidial compounds promote the activity of *Myxococcus faecalis* DK1622 against pathogenic fungi. Fusarium oxysporum f. sp. from Cuba P4 is a predation diagram, where A and B represent the effects of in vitro addition and in vivo expression of cystobactamids-like compounds on *Myxococcus faecalis* DK1622, respectively. Fusarium oxysporum f. sp. from Cuba P4 predation.
[0037] Figure 9 Cystoccidial compounds promote the activity of *Myxococcus faecalis* DK1622 against pathogenic fungi. Corynespora cashew nutA diagram illustrating P9's predation behavior, where A and B represent the effects of in vitro addition and in vivo expression of cystobactamids-like compounds on *Myxococcus faecalis* DK1622, respectively. Corynespora cassicola P9 predation.
[0038] Figure 10 This study demonstrates the predation of other pathogenic fungi by DK1622 after the addition of cystobactamids-like compounds in vitro.
[0039] Figure 11 This diagram illustrates the control effects of different treatments on banana anthracnose. In the diagram, P1 represents the control group inoculated with TPM buffer, DK1622-cys represents the treatment group treated with the inoculum prepared by strain DK1622-cys, and DK1622 represents the treatment group treated with Fungobacterium flavum DK1622. Detailed Implementation
[0040] It should be noted that the following detailed descriptions are exemplary and intended to provide further illustration of the invention. Unless otherwise specified, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains.
[0041] It should be noted that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to limit the exemplary embodiments of the present invention. As used herein, the singular form is intended to include the plural form as well, unless the context clearly indicates otherwise. Furthermore, it should be understood that when the terms "comprising" and / or "including" are used in this specification, they indicate the presence of features, steps, operations, and / or combinations thereof.
[0042] The culture medium formulation in the examples is as follows:
[0043] PDA medium formulation: 12 g / L potato extract powder, 20 g / L glucose, 10 mM 15 g / L agar powder (solid medium), pH 5.6.
[0044] CTT medium formulation: 10 g / L casein peptone, 1.97 g / L MgSO4•7H2O, 10 mM Tris-HCl, 1 mM K2HPO4 / KHPO4, 15 g / L agar powder (solid medium), pH 7.6.
[0045] VY / 2 medium formulation: 5 g / L Angel yeast, 1 g / L MgSO4•7H2O, 0.7 g / L CaCl2, 15 g / L agar powder (solid medium), pH adjusted to 7.2.
[0046] TPM buffer formulation: 1.97 g / L MgSO4•7H2O, 10 mM Tris-HCl, 1 mM K2HPO4 / KH2PO4, pH 7.6.
[0047] In this invention, the destroyer coral cocci ( Corallococcus killer SDUN13 was obtained in August 2019 in Qingdao, Shandong Province, China, by the destroyer coral cocci ( ). Coralloccus murderer SDUN13 has been deposited at the China General Microbiological Culture Collection Center (CGMCC) on November 7, 2025, with accession number CGMCC No. 36542. The deposit address is: No. 3, Courtyard 1, Beichen West Road, Chaoyang District, Beijing, Institute of Microbiology, Chinese Academy of Sciences.
[0048] The myxobacteria in this invention include Myxococcus stipitatus 09-20S1、 Myxococcus stocky HXWNN15 Myxococcus virescens SDUN12 Myxococcus virescens 179B01 Myxococcus virescens HXWNN29 Myxococcus virescens 122B12, Myxococcus fulvus 09-20S4 Myxococcus fulvus HXWNN20 Corallococcus macrosporus 20-3S1, Coralloccus macrosporum HXWNN19 Corallococcus killer HXWNN13 Coralloccus murderer VnMB02、 Corallococcus small HXWNN7 Corallococcus small HXWNN16 Nannocystis pusilla 09-2S35 Nannocystis pusilla QLN3, Nannocystis edens QLN2, Archangium gephyra SDU294 Archangel violet SM1-4 Pyxidicoccus deceitful 9741B01 Aggregicoccus edonensis SDU12 Myxococcus xanthus DK1622 was isolated and purified by Professor Li Yuezhong's research group at Shandong University. It is available to the public from the Institute of Microbial Technology at Shandong University and is only for the purpose of replicating this invention. It may not be used for any other purpose.
[0049] Further explanation is needed regarding the strain " Myxococcus xanthusThe Chinese term for "DK1622" is also known as *Myxococcus faecalis* DK1622. In this article, it will be consistently referred to as *Myxococcus faecalis* DK1622. Information regarding this strain has been published in the literature "Essence Analysis of Genome Islands of *Myxococcus faecalis* DK1622 and Its Role in Cell Population Behavior," Li Xia, 2013.
[0050] Animal pathogenic bacteria include E.coli K12 A. baumannii ATCC 17978 and S.aureus ATCC12600, originally purchased commercially; plant pathogenic fungi. F. oxysporum P4 Colletotrichum musae ACCC 31244 Colletotrichum asianum P3 Fusarium oxysporum f.sp. from Cuba P4 Fusarium oxysporum f. sp. beans P5 Fusarium wilt P6 Fusarium gramineae P7 Fusarium mango trees P8 Corynespora cassicola P9 Nectarine sp. P11、 Fusarium wilt P12, Fusarium oxysporum ACCC 30373 was kindly provided by Professor Li Gang's research group at Qingdao University.
[0051] To enable those skilled in the art to better understand the technical solution of the present invention, the technical solution of the present invention will be described in detail below with reference to specific embodiments.
[0052] Example 1: Destroyer Coral Cocci ( Corallococcus killer Analysis of the biosynthetic gene clusters (cys) of cystobactamids in SDUN13
[0053] High molecular weight genomic DNA was extracted using a genomic DNA sequencing kit (Oxford Nanopore Technologies Inc.). Whole-genome sequencing was performed by Wuhan Benagan Technology Co., Ltd., using a hybrid approach combining second-generation Illumina and third-generation Nanopore technologies. The obtained long and short reads were then assembled into a complete genome using Unicycler software (v0.4.8). Subsequently, gene prediction and functional annotation of the SDUN13 genome were performed using the online website antiSMASH.
[0054] Among them, the biosynthetic gene clusters (cys) corresponding to cystobactamids-like compounds in SDUN13 are as follows: Figure 1As shown, specific annotation information is provided in Table 1. The complete DNA sequence of this cys gene cluster is shown as SEQ ID NO: 1 in the sequence listing of the specification, with a full length of 44,846 bp. This gene cluster contains 21 open reading frames (ORFs), among which the core biosynthetic genes are cys10 (SEQ ID NO: 2), cys11 (SEQ ID NO: 3), cys13 (SEQ ID NO: 4), and cys14 (SEQ ID NO: 5), which encode nonribosomal peptide synthases (NRPS).
[0055] Table 1. Annotation of biosynthetic genes for cystobactamids compounds.
[0056]
[0057] Example 2 Destroyer Coral Cocci ( Corallococcus killer Functional verification of the biosynthetic gene cluster of cystobactamids in SDUN13
[0058] (1) Construction of cystobactamids-type compound biosynthetic gene cluster knockout plasmids: The construction process is as follows Figure 2 As shown, an approximately 1 kb fragment of the cys13 gene was amplified by PCR from the genomic DNA of Corallococcus interemptorSDUN13 using Novizan's high-fidelity enzyme kit (P515-01). Simultaneously, the pBJ113 vector was linearized using PCR. The pBJ113 linear vector was ligated to a 1 kb cys13 gene fragment using the 113 homologous recombinase (Novizan) at 37°C for 30 min, followed by transformation into *E. coli* DH5α. After single-cell growth on plates, the recombinant plasmid was verified using primers pBJ-cys13-check-F / R. The correctly sequenced recombinant plasmid was named pBJ113-Δcys13 and used for subsequent electroporation of myxobacteria.
[0059] (2) Electroporation knockout of the cys gene cluster in *Cytoplasma sphaeroides* SDUN13: *Cytoplasma sphaeroides* SDUN13 was cultured to OD... 600≈1. Collect 8 mL of bacterial cells, wash the cells three times with ice-cold, sterile ddH2O, and finally resuspend the cells in 400 μL of ddH2O. Add 200 ng of pBJ113-Δcys13 plasmid to a 1.5 mL EP tube containing 100 μL of *Coccus corallis*, mix gently, and transfer to a 2 mm electroporation cuvette. Electroporation instrument program settings: resistance: 400 Ω, capacitance: 25 μF, voltage: 1250 V. Place the cuvette in the electroporator for electroporation. Immediately after electroporation, add 1 mL of VY / 2 liquid medium, mix well, transfer to a sterile EP tube, seal with sealing film, and incubate at 30℃ for 1 h. Take 100 μL of bacterial suspension and spread it evenly on a VY / 2+Kan plate (40 μg / mL kanamycin). Seal the plate with sealing film and incubate upside down at 30℃ for 12 h.
[0060] (3) Colony PCR verification: After single colonies grow on the plate, scrape off an appropriate amount of bacterial material and resuspend it in 50 μL ddH2O. Boil in a metal bath at 100℃ for 5 min, then place on ice for 5 min. Repeat this cycle 3 times. After centrifuging the bacterial solution at high speed, use primers Δcys13-check-F1 / R1 and Δcys13-check-F2 / R2 to perform PCR verification on the treated bacterial solution. The verification results are as follows: Figure 2 As shown. The correct strain obtained through screening was named SDUN13-Δcys13.
[0061] (4) Product verification of SDUN13-Δcys13 strain: An appropriate amount of bacterial cells was scraped from a VY / 2+Kan plate and inoculated into VY / 2+Kan liquid medium and cultured for 6-7 days. The bacterial culture was then centrifuged (8000 rpm, 5 min), and the supernatant was extracted three times with the same volume of ethyl acetate. The collected organic supernatants were combined, evaporated to dryness at 37℃, dissolved in 1 mL of methanol, and then detected by LC / MS.
[0062] High performance liquid chromatography conditions: Chromatographic analysis was performed on a Thermo Fisher Scientific UltiMate 3000 with an EF column. C18M (5μm, 250mm x 4.6mm, GALAK), UV detector, detection wavelength 280 nm, detection temperature 30℃, injection volume 10 μL, flow rate 0.8 mL / min, mobile phase A is ddH2O, mobile phase B is methanol, gradient elution, elution program as follows: 0-30 min: 5-100% B; 30-40 min: 100% B; 40-46 min: 5% B.
[0063] The results of high performance liquid chromatography analysis are as follows: Figure 3As shown: the secondary metabolites of SDUN13-Δcys13 strain did not have the characteristic absorption peak corresponding to cystobactamids at around 30 min, indicating that the cystobactamids biosynthetic gene cluster of SDUN13 was successfully knocked out, and cys is indeed the gene cluster corresponding to the compound cystobactamids.
[0064] The sequence of the 1 kb cys13 gene fragment is shown in SEQ ID NO:6, the sequence of the pBJ113 vector is shown in SEQ ID NO:7, and the primers used are shown in Table 2.
[0065] Table 2 Primer Sequences
[0066]
[0067] Example 3: Heterologous expression of biosynthetic gene clusters of cystobactamids-like compounds
[0068] (1) Construction and screening of the SDUN13 BAC library: A linearized BAC vector was prepared. SDUN13 cells were embedded in an agarose gel and lysed to obtain ultra-long (>300kb) and complete genomic DNA. The genomic DNA was then digested to obtain large fragments with random breaks. Target fragments of 100-300 kb were accurately recovered using pulsed-field gel electrophoresis. The large DNA fragments were ligated to the BAC vector and introduced into E. coli Top10 via electroporation. Recombinant clones were screened, and the average insert size and library coverage were evaluated (usually requiring more than 10-fold genomic coverage). The above steps were outsourced to Wuhan Bakexing Biotechnology Co., Ltd. Primers cys-check-F / R were designed, and strains containing the cys gene cluster were screened from 384-well plates returned by the company using PCR.
[0069] (2) Construction of BAC-Tpase-cys plasmid: The constructed plasmid was electroporated into GB05-Red strain; then, the BAC-Tpase vector was linearized using Novizan's high-fidelity enzyme (P515-01 kit), carrying a 50bp cys homologous sequence. 200 ng of the linear BAC-Tpase vector was transformed into GB05-Red strain containing the cys gene cluster via linear circular recombination. Kan was used for resistance selection. After single bacteria grew on the plate, the plasmid was verified using primers pBAC-cys-check-F1 / R1 and pBAC-cys-check-F2 / R2. The recombinant plasmid that was correctly identified by sequencing was named pBAC-Tpase-cys and used for subsequent electroporation of myxobacteria. The sequence of the BAC-Tpase vector is shown in SEQ ID NO: 8.
[0070] (3) pBAC-Tpase-cys transformation into *Myxococcus faecalis* DK1622
[0071] Yellow slime cocci ( Myxococcus xanthus DK1622 cultured to OD 600 ≈1. Collect 8 mL of bacterial cells, wash the cells three times with ice-cold, sterile ddH2O, and finally resuspend the cells in 400 μL of ddH2O. Add 200 ng of pBAC-Tpase-cys plasmid to a 1.5 mL EP tube containing 100 μL of *Coccus corallis*, mix gently, and transfer to a 2 mm electroporation cuvette. Electroporation instrument program settings: resistance: 400 Ω, capacitance: 25 μF, voltage: 1250 V. Place the cuvette in the electroporator for electroporation. Immediately after electroporation, add 1 mL of CTT liquid medium, mix well, transfer to a sterile EP tube, seal with sealing film, and incubate at 30℃ for 1 h. Take 100 μL of bacterial suspension and spread it evenly on a CTT+Kan plate (40 μg / mL kanamycin). Seal the plate with sealing film and incubate upside down at 30℃ for 12 h.
[0072] (4) Colony PCR verification
[0073] After single bacteria have grown on the plate, a suitable amount of bacterial culture is scraped off and resuspended in 50 μL of ddH2O. The culture is then boiled in a metal bath at 100℃ for 5 min, followed by incubation on ice for 5 min. This cycle is repeated three times. After high-speed centrifugation, the treated bacterial culture is verified by PCR using primers pBAC-cys-check-F1 / R1 and pBAC-cys-check-F2 / R2. The verification results are as follows: Figure 4 As shown in the table. The correctly screened strain was named DK1622-cys. The primers used are shown in Table 3.
[0074] Table 3 Primer Sequences
[0075]
[0076] (5) Product verification and collection of DK1622-cys strain
[0077] A suitable amount of bacterial cells was scraped from a CTT+Kan plate and inoculated into CTT+Kan liquid medium (40 μg / mL kanamycin) and cultured for 6–7 days. The bacterial culture was then centrifuged (8000 rpm, 5 min), and the supernatant was extracted three times with the same volume of ethyl acetate. The collected organic supernatants were combined, evaporated to dryness at 37 °C, dissolved in 1 mL of methanol, and then analyzed by LC / MS.
[0078] High performance liquid chromatography analysis results are as follows Figure 5As shown, the secondary metabolites of the DK1622-cys strain exhibit a characteristic absorption peak corresponding to cystobactamids at 30 min, indicating that the cystobactamids biosynthetic gene cluster of SDUN13 was successfully expressed in DK1622, which is the gene cluster corresponding to cystobactamids-like compounds.
[0079] The product eluted for 25-30 minutes, i.e., the mixture of cystobactamids-like compounds, is collected for subsequent experiments.
[0080] Example 4: Effects of cystobactamids-like compounds on the original bacterium SDUN13
[0081] (1) Culture medium preparation: Melt the TPM solid culture medium and pour it into a sterile 12-well plate. Let it stand until it solidifies before use.
[0082] (2) Bacterial culture: Prey bacteria: Pathogenic bacteria ( E.coli K12 A. baumannii ATCC 17978 F. oxysporum P4 and S.aureus ATCC12600 was inoculated into LB liquid medium and cultured overnight at 37°C with shaking until the late logarithmic growth phase (OD). 600 =0.8-1.0). Myxobacteria: Inoculate SDUN13-wt and SDUN13-Δcys strains into CTT liquid medium and culture at 30°C with shaking until mid-log (OD). 600 =0.5-0.6).
[0083] (3) Plating and spot inoculation: Preparation of prey bacterial layer: Collect pathogens, wash three times with TPM buffer, and resuspend; adjust the cell density of pathogens to OD 600 It is 100 (approximately 1 × 10⁻⁶) 11 (cells / mL); Take 100 μL of overnight cultured bacterial suspension and evenly spread it on the surface of a solidified TPM plate (containing cystobactamids or DMSO). Invert the plate and incubate at 37°C for 1-2 h to allow the bacteria to fully adsorb onto the agar surface. At this time, a thin, translucent bacterial moss will form. Spot inoculation of myxobacteria: Collect myxobacteria, wash three times with TPM buffer, and resuspend; adjust the cell density of myxobacteria to OD. 600 It is 35 (approximately 5 × 10). 9(cells / mL); On a plate already covered with prey bacteria, carefully place 1 μL of concentrated myxobacterial culture in the center of the plate using a micropipette. Allow the culture to be completely absorbed by the agar before transferring the plate (let it stand for about 10-15 min). Take images of the predation every 24 h using a Nikon SMZ18 stereo microscope.
[0084] The test results are as follows Figure 6 As shown, when the cys gene cluster of the SDUN13 strain was knocked out, the predation ability of the SDUN13-Δcys strain against various pathogens decreased significantly compared with the wild type, indicating that the cys gene cluster and the cystobactamids-like compounds synthesized by it can effectively improve the predation ability of SDUN13 against different pathogens.
[0085] Example 5: Cystobactamids-like compounds can effectively promote the predation of pathogens by other myxobacteria.
[0086] (1) Culture medium preparation: After melting the TPM solid culture medium, pour it into a sterile 12-well plate. Experimental group: Add different concentrations of cystobactamids mixture (0 μg / mL, 0.25 μg / mL and 2 μg / mL) to the wells and mix gently to avoid generating bubbles. Control group: Add the same amount of DMSO solvent as the experimental group to the same amount of TPM culture medium.
[0087] (2) Culture of strains: Prey bacteria: Inoculation with pathogenic bacteria ( A. baumannii ATCC 17978 and F. oxysporum P4) was added to LB liquid medium and cultured overnight at 37°C with shaking until late logarithmic growth (OD). 600 =0.8-1.0). Myxobacteria: Different species of myxobacteria were inoculated into CTT liquid medium and cultured at 30°C with shaking until mid-log (OD). 600 =0.5-0.6).
[0088] (3) Laying boards and spot connection: The method is the same as "(3) Laying boards and spot connection" in Example 4.
[0089] Table 4. Diameter of myxobacteria after treatment in different treatment groups
[0090]
[0091] Note: The units of values in the table are millimeters (mm), and wt indicates slime bacteria without added cystobactamids.
[0092] Table 4 shows the types of myxobacteria treated and the diameters of myxobacteria after different treatment groups. The predatory abilities of some strains are also shown in Table 4. Figure 7As shown, it can be concluded that during the culture process, the exogenous addition of a mixture of cystobactamids can effectively improve the resistance of different species of myxobacteria to... A. baumannii ATCC 17978 and F. oxysporum P4's predation ability is such that the suitable concentration of a mixture of cystobactamids for some myxobacteria is 0.25 μg / mL, and the suitable concentration of a mixture of myxobacteria for others is 2 μg / mL.
[0093] Example 6: Cystoccidial compounds can effectively enhance the predation ability of *Myxococcus faecalis* DK1622 against various plant pathogenic fungi.
[0094] 1. In vitro addition
[0095] (1) Culture medium preparation: After melting the TPM solid culture medium, pour it into sterile 12-well plates. Experimental group: Add different concentrations of cystobactamids compounds (0 μg / mL, 0.25 μg / mL, 2 μg / mL and 8 μg / mL) to the wells and mix gently to avoid generating bubbles. Control group: Add the same amount of DMSO solvent as the experimental group to the same amount of TPM culture medium.
[0096] (2) Culture of fungal strains: Prey fungi: Plant pathogenic fungi were inoculated into LB liquid medium and cultured overnight at 37°C with shaking until the late logarithmic growth stage (OD). 600 =0.8-1.0).
[0097] Myxobacteria: Inoculate DK1622 strain into CTT liquid medium and culture at 30°C with shaking until mid-log (OD200). 600 =0.5-0.6).
[0098] (3) Laying boards and spot connection: The method is the same as "(3) Laying boards and spot connection" in Example 4.
[0099] Table 5. Diameter of *Myxococcus faecalis* DK1622 after treatment with different treatment groups for plant pathogenic fungi.
[0100]
[0101] Note: The units of values in the table are millimeters (mm), and wt represents yellow myxococcus DK1622 without added cystobactamids.
[0102] The results showed that the in vitro addition of cystobactamids significantly enhanced the predation ability of *Myxococcus faecalis* DK1622 against pathogens. The predation diameter is shown in Table 5, and the predation zone is as follows: Figure 10As shown, this indicates that cystobactamids-like compounds can effectively enhance the predation ability of *Myxococcus faecalis* DK1622 against different pathogens.
[0103] 2. In vivo expression
[0104] (1) Culture medium preparation: Melt the TPM solid culture medium and pour it into a sterile 12-well plate. Let it stand until it solidifies before use.
[0105] (2) Bacterial culture: The culture of prey bacteria is the same as that of myxobacteria; DK1622-cys strain is inoculated into CTT-Kan liquid medium and cultured at 30°C with shaking until the mid-log phase (OD50). 600 =0.5-0.6).
[0106] (3) Laying boards and spot connection: The method is the same as "(3) Laying boards and spot connection" in Example 4.
[0107] like Figure 8 A and B in Figure 9 As shown in A and B, both the addition of cystobactamids-like compounds in vitro and the heterologous expression of strain DK1622-cys significantly improved the predation ability against pathogens, indicating that the cys gene cluster and the cystobactamids-like compounds it synthesizes can effectively enhance the predation ability of *Myxococcus faecalis* DK1622 against different pathogens.
[0108] Example 7 Preparation and application of microbial inoculants
[0109] (1) Preparation of bacterial agent: Myxobacterium DK1622-cys was inoculated into CTT liquid medium and cultured at 30℃ with shaking for 24 h. Then it was transferred to VY / 2 liquid medium and cultured for 48 h. The bacterial cells were collected, resuspended with TPM buffer and the concentration was adjusted to OD. 600 ≈0.3, which is the microbial inoculant (myxobacterial inoculant); the preparation method of yellow myxococcus DK1622 suspension is the same as above.
[0110] (2) Preparation of banana anthracnose spore suspension: Banana anthracnose spores were inoculated on PDA medium and cultured for 5 days. 20 mL of sterile water was added and the supernatant was gently scraped off, collected, centrifuged, resuspended in TPM buffer, and its concentration was adjusted to OD. 600 ≈0.3-0.5, which is the spore liquid of the pathogen.
[0111] (3) Banana fruit puncture experiment: Select banana fruits of similar shape and size, and disinfect them with 75% ethanol for 30 s and 2% NaClO for 2 min respectively. Rinse them three times with sterile water and air dry. Puncture the fruit surface with a sterile punch (5 mm in diameter), making three wounds on each fruit. Inoculate each wound with 20 μL of banana anthracnose fungus ( Colletotrichum musae ACCC 31244) spore suspension, 2 h later, 20 μL myxobacterial suspension was inoculated, and the control group was inoculated with 20 μL TPM. After drying, the spores were placed in a plastic bag and cultured at 30℃. The disease development was observed.
[0112] The test results are as follows Figure 11 As shown, a microbial inoculant made from myxobacterium DK1622-cys can effectively reduce the damage of bananas caused by anthracnose.
[0113] Finally, it should be noted that the above description is merely a preferred embodiment of the present invention and is not intended to limit the present invention. Although the present invention has been described in detail with reference to the foregoing embodiments, those skilled in the art can still modify the technical solutions described in the foregoing embodiments or make equivalent substitutions for some of them. Any modifications, equivalent substitutions, improvements, etc., made within the spirit and principles of the present invention should be included within the protection scope of the present invention.
Claims
1. A biosynthetic gene cluster of cystobactamids, characterized in that, The nucleotide sequence of the biosynthetic gene cluster is shown in SEQ ID NO:
1.
2. An engineered bacterium containing the biosynthetic gene cluster of claim 1, characterized in that, The host cell of the engineered bacteria is Myxococcus xanthus DK1622.
3. A microbial inoculant, characterized in that, It contains the engineered bacteria as described in claim 2.
4. The application of the microbial agent according to claim 3 in promoting the predation ability of myxobacteria on pathogenic bacteria, characterized in that, The myxobacteria are Myxococcus xanthus DK1622; The pathogenic bacteria include animal pathogenic bacteria and plant pathogenic fungi; the animal pathogenic bacteria are... E. coli K12 A. baumannii ATCC 17978 and S.aureus ATCC 12600; the plant pathogenic fungus is F. oxysporum P4 Colletotrichum musae ACCC 31244 Colletotrichum asianum P3 Fusarium oxysporum f.sp. cubense P4 Fusarium oxysporum f. sp. phaseoli P5 Fusarium foetens P6 Fusarium graminearum P7 Fusarium mangiferae P8 Corynespora cassiicola P9 Nectria sp. P11、 Fusarium foetens P12, Fusarium oxysporum ACCC 30373.
5. The application of the microbial agent according to claim 3 in inhibiting plant pathogens, characterized in that, The plant pathogen is *Anthracnose fungus*.
6. A method for inhibiting plant pathogens, characterized in that, The microbial agent according to claim 3 is used to inhibit plant pathogens; the plant pathogen is *Anthracnose glomeratus*.
Citation Information
Patent Citations
Engineering strain used for heterologously expressing Disorazole Z efficiently, gene cluster for establishing strain and application of strain
CN108048472A
Novel cystobactamide derivatives
CN110997627A
